Home Tags Pfizer
Array BioPharma spikes more than 50% after Pfizer shells out $11 billion for the cancer-drug developer
Pfizer's blockbuster deal for Array BioPharma is the latest in a growing list of M&A deals to take place in the cancer-treatment space this year.
EpiPens weren’t working. It took 3 years and the FDA stepping in before serious change — with potentially deadly outcomes
Consumer complaints about EpiPens were increasing, but its manufacturer wasn’t properly looking into those complaints, FDA inspectors warned in 2014.
Drug giant Pfizer isn’t ready to abandon neuroscience — here’s its $150-million ‘star cluster’ strategy for betting on p...
Execs from pharma giant Pfizer shared their strategy for keeping an eye on neuroscience — if not from the front row, then at least from the sidelines.
Trump may have shamed Pfizer for increasing drug prices, but that isn’t stopping drugmakers from doing more of the same
Pharmaceutical companies are increasing drug price again this month, and they could be even larger than usual.
Two huge drugmakers are spinning off iconic brands like Advil, ChapStick and Emergen-C with nearly $13 billion in sales — and it’s part of...
The products involved in the deal are familiar pharmacy names, but they also have lower margins than other medicines.
GlaxoSmithKline will be broken up in a megadeal with Pfizer that could change the face of global healthcare
The joint venture could have combined sales of nearly $10 billion.
Opioid overdose deaths are highest in places where pharma spends the most on marketing, a new study finds
Researchers at the University of Pittsburgh launched a study to figure out if there's a link between the money that drugmakers spend on opioid marketing and drug-related deaths.
Pfizer CEO Ian Read is stepping down at the end of 2018, ending his eight-year tenure at the head of the pharma giant. He'll be replaced by Pfizer chief operating officer Albert Bourla in January 2019.
Pfizer’s long-serving CEO, Ian Read, is standing down and being replaced by his chief operating officer
Read, who has been at the helm of the firm since 2010, will stand down on January 1, the company announced Monday. He will be replaced by Pfizer's chief operating officer, Albert Bourla.
After a conversation between President Donald Trump and Pfizer CEO Ian Read, Pfizer said it plans to defer the price increases, returning the prices to where they were before July 1 "as soon as technically possible," the company said in a statement.